Loading
A phase 2 trial of bevacizumab in lung cancer, run by Maastricht University Medical Center, now recruiting.
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases is a phase 2, interventional study registered as NCT06401824 by Maastricht University Medical Center, with a registry enrolment figure of 25 participants, started 2025-04-24 and due to reach its primary completion in 2026-11-01. Interventions recorded: Sacituzumab Govitecan-Hziy 180 MG plus bevacizumab. Conditions listed: NSCLC Stage IV; Brain Metastases, Adult. Primary outcome: brain metastases overall response rate (ORR). Lung eligibility wording from the registry: "Pathology proven metastatic non-squamous NSCLC". Sites: Netherlands. No results are recorded here; the registry entry is the source.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Bevacizumab, Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Monoclonal antibodies and the tag lung-deep-dive.
Shares Anti-angiogenic therapy, Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.